Skip to main content

Remote Job Finders (RJF)

JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma’s strategy at J.P. Morgan on Monday.

AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient basis. In exchange, the pharma secured exemptions from tariffs and other future pricing directives.

AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market

The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
Scroll to top